RG1068 (Synthetic Human Secretin)
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout RG1068 (Synthetic Human Secretin)
RG1068 (Synthetic Human Secretin) is a phase 3 stage product being developed by Repligen for Autism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00036231. Target conditions include Autism.
What happened to similar drugs?
0 of 9 similar drugs in Autism were approved
Approved (0) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00660335 | Phase 3 | Completed |
| NCT00216294 | Phase 2 | Completed |
| NCT00036231 | Phase 3 | Terminated |
| NCT00036244 | Phase 3 | Completed |
Competing Products
20 competing products in Autism